Opening a facility to produce advanced drugs for treating oncology

Mubadala Bio, the national company specialized in pharmaceutical manufacturing, which aims to strengthen the pharmaceutical manufacturing system in the UAE, announced the opening of the highly effective pharmaceutical facility affiliated with its company, Bioventure Healthcare, and the launch of three essential medicines for the treatment of oncology, some of which are produced locally for the first time as alternative medicines.

The facility was designed with international specifications specifically to deal with complex and highly effective pharmaceutical products, including oncology and hormone drugs, and was built according to the highest standards of safety and quality to match the requirements of international specifications.

The first drugs that will be launched in this facility include: “Lenalidomide,” which is used to treat multiple myeloma (multiple myeloma), a type of blood cancer, and “Pomalidomide,” which is a drug produced locally for the first time in the UAE, and is also used to treat multiple myeloma, as it provides an additional treatment option to control the disease, and “Sunitinib,” which is a targeted therapy used to treat types of cancer. Specific advanced or worsening cancer.

By providing these vital medicines in the local market, “Mubadala Bio” contributes to enhancing drug security, ensuring the continuity of supplies, and providing more cost-efficient treatment options for patients throughout the UAE. The CEO of the UAE Investment Sector at Mubadala and Chairman of the Board of Directors of “Mubadala Bio”, Dr. Bakhit Al Kathiri, said that launching these medicines locally to treat oncology contributes to the development of the pharmaceutical industries in the country and enhances their progress.

Mubadala Bio CEO, Dr. Issam Mohammed, said that the company is committed to strengthening the pharmaceutical production system in the UAE.